After more than 20 years of research, a new vaccine that promises to fight Alzheimer's symptoms, is being tested in humans, by researchers from United Euroscience , having already shown very positive and promising results, with a response rate of almost 100%. To be made available on the market, more tests on humans are needed to confirm the safety of the vaccine.
Alzheimer's is a disease characterized by the progressive degeneration of brain neurons and the consequent impairment of their cognitive functions, such as memory, attention, language, orientation, perception, reasoning and thinking, which can compromise the person's quality of life.
The new vaccine that is being studied, may prevent the degeneration of neurons and prevent the evolution of the disease. Learn how to identify the signs and symptoms of Alzheimer's.
How will the vaccine work?
The specific cause of Alzheimer's is not yet known, but it is believed that the disease is caused by the accumulation of lacquers composed of two proteins, called Beta-amyloid protein and Tau protein, which cause inflammation, disorganization and destruction of neuronal cells, mainly in the brain regions called the hippocampus and cortex, leading to memory loss and causing cognitive damage.
The vaccine that is now being studied, has in its composition a peptide called UB-311, which is composed of a chain of amino acids from the beta-amyloid protein. This peptide was created to trigger an antibody response in the body, which recognizes, connects and eliminates the beta-amyloid protein, responsible for the destruction of neuronal cells, preventing the progression of the disease.
When it will be available?
Before making the vaccine available on the market, it will be necessary to carry out more clinical tests on humans, in order to test the safety and to verify the possible side effects associated with the treatment. Phase 2 clinical trials are now underway in humans that will receive multiple doses of the vaccine, and will be evaluated for about 2 years, in order to determine the effects of long-term treatment. The results of this study are estimated to be completed in March 2021.
